Cheng Andrew's Form 4 filing
Akero Therapeutics, Inc. (AKRO) · filed May 13, 2025
- Accession no.
- 0000950170-25-070811
- Filed
- May 13, 2025
- Trade date
- May 12, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $1.24M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cheng AndrewCIK 0001778307 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 12, 2025 | Common Stock | SSaleDisposed | −7,200 | $41.00 | −$295,200 | 617,124 | Direct | |
| May 12, 2025 | Common Stock | SSaleDisposed | −22,800 | $41.63 | −$949,164 | 594,324 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.